Hepatology International · 2014 · 32 citations · 36 references
MedicineCell BiologyImmunologyCancer ImmunologyImmunoregulationInflammationChronic Liver DiseaseCirrhosisHepatocellular CarcinomaLiver CancerLiver DiseaseViral HepatitisActivated Hepatic Stellate CellsCell Proliferation IndicesHepatic Stellate Cell BiologyHost Immune SuppressionImmune Suppression MechanismsInterferon Gamma ProductionInterferon ProductionWestern Blot Analysis
PURPOSE: To investigate the effects of soluble FGL2 (sFGL2) secreted by hepatic stellate cells (HSCs) on immune suppression in cirrhotic patients with hepatocellular carcinoma (HCC). METHODS: Serum sFGL2 levels were examined by ELISA in 40 patients with HCC, liver cirrhosis (LC) or chronic HBV (CHB) infection. A double staining of the immunofluorescence analysis of α-SMA and FGL2 was performed in two cirrhotic liver specimens. The expression of FGL2 in the LX2 cell line was analyzed by immunofluorescence, Western blot and flow cytometry. T-cells purified from HCC patients using magnetic beads were cultured with LX2 cells at different ratios with anti-CD3-stimulating or FGL2-blocking antibodies. The proliferation index (PI) of CD8 + T cells was assessed by flow cytometry, and the secretion of IFN-γ was measured by ELISA. RESULTS: sFGL2 levels are significantly higher in patients with HCC or LC compared with those with CHB (p = 0.0039/p = 0.0020). Among HCC patients, those with cirrhosis exhibited significantly higher levels of sFGL2 compared with non-cirrhotic individuals (p = 0.0108). The expressions of FGL2 and α-SMA overlapped in HSCs in liver specimens. FGL2 protein secreted by LX2 cells inhibited T-cell proliferation of HCC patients in a dose-dependent manner in vitro. The PI of CD8 + T cells was significantly enhanced following addition of FGL2 antibody to the culture system (LX2/T-cell ratio of 1:10, p = 0.002). The level of IFN-γ in mixed cultures was inversely correlated with the number of HSCs and was reversed by incubation with FGL2 blocking antibody. CONCLUSION: sFGL2 protein is a novel effector molecule of activated HSCs, which suppresses CD8 + T cell proliferation and interferon-γ production, and it subsequently might contribute to immune suppression during fibrosis and tumorigenesis in the liver.
36
Dong Xu, Xingxing He, Ying Chang et al. · Hepatogastroenterology · 2012 · 2K citations
The global burden of cancer: priorities for prevention
M. J. Thun, John O. L. DeLancey, Ahmedin Jemal et al. · Carcinogenesis · 2009 · 1.1K citations · Full text
Ito Cells Are Liver-Resident Antigen-Presenting Cells for Activating T Cell Responses
Florian Winau, Guido Hegasy, Ralf Weiskirchen et al. · Immunity · 2007 · 401 citations · Full text